1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
Saved in:
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
格式: | Artigo |
語言: | 英语 |
出版: |
2020
|
在線閱讀: | https://doi.org/10.1016/j.annonc.2020.08.1730 http://www.annalsofoncology.org/article/S0923753420417260/pdf |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
成為第一個發表評論!